Literature DB >> 15548718

Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma.

Ronald J C L M Vuylsteke1, Barbara G Molenkamp, Hester A Gietema, Paul A M van Leeuwen, Pepijn G J T B Wijnands, Wim Vos, Paul J van Diest, Rik J Scheper, Sybren Meijer, Tanja D de Gruijl.   

Abstract

The initial tumor-draining lymph node, the sentinel lymph node, not only constitutes the first expected site of micrometastasis but also the first point of contact between tumor-associated antigens and the adaptive immune system. A tumor-induced decrease in the frequency and activation state of sentinel lymph node dendritic cells will impair the generation of effective antitumor T-cell responses and increase the likelihood of metastatic spread. Here, we demonstrate that intradermal administration of granulocyte macrophage-colony stimulating factor around the excision site of stage I primary melanoma tumors increases the number and activation state of dendritic cells in the paracortical areas of the sentinel lymph node and enhances their binding to T cells. We conclude that local treatment of melanoma patients with granulocyte macrophage-colony stimulating factor, before surgery, conditions the sentinel lymph node microenvironment to enhance mature dendritic cell recruitment and hypothesize that this may be more conducive to the generation of T-cell-mediated antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548718     DOI: 10.1158/0008-5472.CAN-03-3251

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.

Authors:  Booyeon J Han; Joseph D Murphy; Shuyang Qin; Jian Ye; Taylor P Uccello; Jesse Garrett-Larsen; Brian A Belt; Peter A Prieto; Nejat K Egilmez; Edith M Lord; David C Linehan; Bradley N Mills; Scott A Gerber
Journal:  Immunol Invest       Date:  2020-06-04       Impact factor: 3.657

2.  Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells.

Authors:  Barbara G Molenkamp; Ronald J C L M Vuylsteke; Paul A M van Leeuwen; Sybren Meijer; Wim Vos; Pepijn G J T B Wijnands; Rik J Scheper; Tanja D de Gruijl
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

3.  Fluorine-19 Cellular MRI Detection of In Vivo Dendritic Cell Migration and Subsequent Induction of Tumor Antigen-Specific Immunotherapeutic Response.

Authors:  Corby Fink; Michael Smith; Jeffrey M Gaudet; Ashley Makela; Paula J Foster; Gregory A Dekaban
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

Review 4.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 5.  Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity.

Authors:  Mahmoud R Hussein
Journal:  Int J Exp Pathol       Date:  2006-06       Impact factor: 1.925

Review 6.  CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.

Authors:  Basav N Hangalapura; Laura Timares; Dinja Oosterhoff; Rik J Scheper; David T Curiel; Tanja D de Gruijl
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.565

7.  In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

Authors:  Jurjen M Ruben; Hetty J Bontkes; Theresia M Westers; Erik Hooijberg; Gert J Ossenkoppele; Arjan A van de Loosdrecht; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

8.  Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

Authors:  John M Kirkwood; Sandra Lee; Stergios J Moschos; Mark R Albertini; John C Michalak; Cindy Sander; Theresa Whiteside; Lisa H Butterfield; Louis Weiner
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

9.  Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.

Authors:  Rieneke van de Ven; Jelle J Lindenberg; Dinja Oosterhoff; M Petrousjka van den Tol; Rodney A Rosalia; Miho Murakami; Maaike Everts; George L Scheffer; Rik J Scheper; Tanja D de Gruijl; David T Curiel
Journal:  J Immunother       Date:  2009 Nov-Dec       Impact factor: 4.456

Review 10.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.